Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01580384 · ClinicalTrials.gov registry record

A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome

A clinical trial of Down Syndrome, sponsored by Hoffmann-La Roche.

Completed
Registry status
90
Enrollment target
12
Study locations

NCT01580384: Completed study of Down Syndrome, sponsored by Hoffmann-La Roche.

NCT01580384 is a study of Down Syndrome that has completed, run by Hoffmann-La Roche. The registered enrollment target is 90 participants, below the 2,470-participant average among 54 other Down Syndrome trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01580384, a study of Down Syndrome, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
90 participants
Enrollment target
12
Study locations

Study Summary

This non-drug, longitudinal, multi-center, multi-national study will evaluate the suitability of neurocognitive tests and functioning scales for the measurement of cognitive and functioning changes in individuals with Down Syndrome. Tests will be administered at clinic visits in Weeks 1, (4) and 24. The duration of the study for each individual will be between 24 and 27 weeks.

Conditions Studied

Down Syndrome

Study Locations (12)

Other

  • - Ciudad Autonoma de Bs As
  • - Ciudad de Buenos Aires
  • - Paris
  • - Saint-Etienne
  • - London
  • - Redruth

Arizona

  • - Tucson

North Carolina

  • - Durham

Nova Scotia

  • - Kentville

Lazio

  • - Rome

Sicily

  • - Palermo

Barcelona

  • - Barcelona

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2012-02
Est. Completion 2014-01
Hoffmann-La Roche

909 total trials

What the finished NCT01580384 record still lists

NCT01580384 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 2,470-participant average among 54 other Down Syndrome trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Down Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT01580384 lists 12 locations in 7 states (Other, Arizona, North Carolina).

Frequently Asked Questions

What is clinical trial NCT01580384 about?

NCT01580384 is a clinical study titled "A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome". This non-drug, longitudinal, multi-center, multi-national study will evaluate the suitability of neurocognitive tests and functioning scales for the measurement of cognitive and functioning changes in individuals with Down Syndrome. Tests will be administered at clinic visits in Weeks 1, (4) and 24....

What is the current status of trial NCT01580384?

This trial is currently completed. The enrollment target is 90 participants. The study started on 2012-02. Estimated completion is 2014-01.

What conditions does trial NCT01580384 study?

This clinical trial studies the following conditions: Down Syndrome.

Who is sponsoring clinical trial NCT01580384?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01580384 being conducted?

This trial has 12 study locations across Arizona, North Carolina, Nova Scotia, Lazio, Sicily. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01580384's enrollment target sits among peer trials

90 25th of 54 higher than 30 of 54 other Down Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Down Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01580384, the US trial registry maintained by the National Library of Medicine. NCT01580384 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.